3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
12
Leukemia
5
Leukemia, Myeloid, Chronic-Phase
4
Leukemia, Myeloid, Accelerated Phase
4
Blast Crisis
4
Neoplasms
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
3
Gastrointestinal Stromal Tumors
2
Gastrointestinal Neoplasms
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome
1
Neoplasms by Histologic Type
1
Myeloproliferative Disorders
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Glioblastoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Medullary
1
Carcinoma
1
Burkitt Lymphoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Interventions
Oxaliplatin
10
Capecitabine
9
Cisplatin
8
Fluorouracil
5
Leucovorin
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
atezolizumab
3
Nivolumab
3
trebananib
2
ponatinib
2
pembrolizumab
2
avelumab
2
apatinib
2
alectinib
2
XELOX
2
Standard of Care
2
S 1 (combination)
2
Radiotherapy
2
Radiosurgery
2
Ocoxin
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
Folfox protocol
2
Everolimus
2
Erlotinib Hydrochloride
2
Acupuncture Therapy
2
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts